China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Update

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totaling 63,863 shares, an increase of 102.2% from the March 15th total of 31,586 shares. Approximately 6.9% of the company’s stock are short sold. Based on an average daily trading volume, of 116,894 shares, the short-interest ratio is presently 0.5 days.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of China SXT Pharmaceuticals to a “sell” rating in a research note on Saturday, February 7th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On China SXT Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in SXTC. Virtu Financial LLC boosted its holdings in China SXT Pharmaceuticals by 107.5% in the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after purchasing an additional 15,013 shares during the period. Citadel Advisors LLC acquired a new position in China SXT Pharmaceuticals in the third quarter worth $78,000. Finally, XTX Topco Ltd acquired a new position in China SXT Pharmaceuticals in the fourth quarter worth $36,000. Institutional investors and hedge funds own 5.02% of the company’s stock.

China SXT Pharmaceuticals Price Performance

China SXT Pharmaceuticals stock remained flat at $2.32 during mid-day trading on Monday. 36,799 shares of the company’s stock were exchanged, compared to its average volume of 283,090. The firm’s fifty day moving average is $2.25 and its 200 day moving average is $120.72. China SXT Pharmaceuticals has a 1 year low of $1.25 and a 1 year high of $1,046.98.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.